ASCO Launches New Survivorship Guidelines
Author: Roxanne NelsonSource: medscape.com The American Society of Clinical Oncology (ASCO) has issued 3 new evidence-based clinical practice guidelines on the prevention and management of common symptoms that affect a large number of cancer survivors — neuropathy, fatigue, and depression and anxiety. The number of cancer survivors in the United States has risen exponentially, from 3.0 million in 1971 to about 13.7 million currently. That is good news, but the downside is that survivors often face long-term health issues related to their disease and treatment. Thus, there is an outstanding need for comprehensive guidance to assist clinicians in this management process. The ASCO recommendations reinforce the fact that both physical and psychological needs have to be addressed in this population. The guidelines, published online April 14 in the Journal of Clinical Oncology, are the first in a series that will focus on survivorship care. Peripheral Neuropathy Chemotherapy-induced peripheral neuropathy (CIPN) is a common treatment-related adverse event and can affect a patient's long-term quality of life. It is estimated that about 38% of patients who are treated with multiple agents develop CIPN, but this can vary, depending on the actual regimen and duration of treatment. Chemotherapy combinations associated with a higher incidence of CIPN are those that involve platinum drugs, vinca alkaloids, bortezomib, and/or taxanes. Symptoms vary, and range from numbness and tingling to shooting pain in the arms and legs. If symptoms are really severe, dose reduction or another regimen might be necessary. For a minority of patients, severe symptoms can last for years. [...]